Answers are grounded in this paper and cite their sources.
Lymphocytes from patients with bladder, renal or prostate carcinomas, or with non‐malignant genito‐urinary disorders, and from normal individuals, were tested in a microcytotoxicity test against cultured bladder cancer cells (T24) and other target cell types. Effector cells were titrated over a range of concentrations against target cells to achieve a quantitative measure of toxicity. Tests were shown to be reproducible by repeat tests of normal donors. Lymphocytes from patients with bladder cancer were more strongly cytotoxic to T24 than lymphocytes from normal healthy donors or from patients with renal or prostatic carcinomas. Cell‐mediated cytotoxicity (CMC) by lymphocytes from bladder‐cancer patients, however, was not significantly stronger than CMC by lymphocytes from patients with non‐malignant GU disorders. Strength of CMC against T24 by lymphocytes from patients with bladder cancer correlated inversely with the extent of disease. Patients with superficial and locally invasive lesions showed strongest anti‐T24 reactivity while patients with disseminated disease had CMC equivalent to normals. In tests against target cells derived from amnion of carcinomas of the breast, cervix and/or colon, CMC by lymphocytes from bladder‐cancer patients was not significantly different from that of any other group. Lymphocytes from all donor groups were cytotoxic at some level to cells from cultures derived from bladder cancer and other tissues, although cell lines differed in apparent vulnerability in CMC tests.
No takes yet. Share an insight, caveat, or question.
Bloom et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: